Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: Glenn who wrote (833)	11/19/1998 1:34:00 AM
From: DavidCG	Read Replies (1) \| Respond to of 90042

CMPD produces #1 osteoporosis diagnostic tool with MERCK, and US govt grants Submitted for FDA marketing approval. CMPD: COMPUMED, INC. (NASDAQ) News first, Analysis to follow >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Wednesday, November 18 Company Press Release SOURCE: CompuMed, Inc. CompuMed OsteoGram(R) Gets Highest Osteoporosis Prediction Score of Any Bone Density Test Ever in Major Clinical Study Results of 3-Year U.S. Study Show OsteoGram Test Dramatically Outperforms Direct Testing of the Spine, Ultrasound, and Competing Hand and Wrist Measurements for Predicting Those Most Likely to Suffer from Osteoporosis MANHATTAN BEACH, Calif., Nov. 18 /PRNewswire/ -- CompuMed, Inc. (Nasdaq: CMPD - news) announced today the results of a landmark 3-year prospective study conducted by scientists from the Hawaii Osteoporosis Foundation, Merck & Co., Inc. (NYSE: MRK - news) and CompuMed under grants from Merck and the U.S. Public Health Service. The findings are published in the latest issue of the highly respected journal Calcified Tissue International. CompuMed's OsteoGram bone density measurements were found to dramatically outperform every other test for identifying those most likely to go on to suffer spinal fractures caused by osteoporosis. The OsteoGram predicted the incidence of future spine fractures with a relative risk of 3.4. Each 10% decrease in bone density as measured by the OsteoGram led to a 3.4 fold (340% greater) increased risk of incurring spine fractures during the course of the study. This is the highest relative risk for predicting spine fractures ever demonstrated by any bone mass measurement technique in a major prospective clinical study. Direct bone density measurements of the spine utilizing expensive, whole body dual-energy x-ray scanners yielded only a 1.9 relative risk for predicting future spine fractures, while competing hand and wrist measurement techniques and heel ultrasound were the least predictive measurements, with relative risks of 1.7, 1.8 and 1.5 respectively. ''The medical community should be very excited about the CompuMed technology,'' said Michael A. Davis, M.D., Ph.D., Professor of Radiology and Director of Radiologic Research at the University of Massachusetts Medical Center. ''Whole body bone scanners can occupy entire exam rooms, cost more than $100,000, take up to 30 minutes to perform a single procedure, and give you less than a 2.0 relative risk for spine fracture prediction. On the other hand, CompuMed technology achieves a 3.4 relative risk, which is dramatically better, and can be integrated into compact, relatively inexpensive units that can perform patient-friendly tests in less than 2 minutes. This is clearly a breakthrough technology.'' The loss of height often seen in people as they age is the result of spinal fractures and collapse caused by osteoporosis and degenerative arthritis. By identifying those most at risk, physicians can provide patients with appropriate therapy that can prevent spinal and other types of osteoporotic fractures, such as hip fractures. Over 28 million Americans currently suffer from osteoporosis, which causes over 1.5 million spine fractures and over 250,000 hip fractures each year. CompuMed is harnessing the power of its bone density testing technology in its new Automated OsteoGram® 2000 and Digital OsteoView® 2000, affordable desktop devices designed to meet the needs of the hundreds of thousands of physicians worldwide who have patients at risk for osteoporosis. CompuMed plans to submit a 510(k) marketing clearance application for the Automated OsteoGram® 2000 to the U.S. Food and Drug Administration within the next few weeks. CompuMed, based in Manhattan Beach, California, develops solutions to important medical problems through the use of computer technology. In addition to the OsteoGram and OsteoView, CompuMed has developed computer-aided telemedicine services for cardiology and currently provides on-line computer interpretation of electrocardiograms (ECGs) to physicians, government and corporate healthcare providers. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> This stock is still on the Nasdaq and currently trades in the .50 range. Basically, what they are claiming is that a 3 year study (with MERCK) shows that they have the best diagnostic tool on the market for predicting osteoperosis. And they are submitting the findings to the FDA in a few weeks in order to get marketing clearance from them. It's a cheaper system, less bulky, and more accurate. 12.4 million OS, 11.3 mil float. 52 week high $1.97 52 week low $.34 Book Value $.17 Cash per Share $.25 Short term price target: $2.00 Chart... this company has been on a constant downslide over the past year. I believe this study is the beginning of an uptrend in this stock again. And of course, an FDA marketing approval would further boost it. And, a possible buyout or marketing agreement from a larger company would support this stock further. This seems imminent to me if this study is as good as CMPD claims. If this study has received the best results from any clinical study out there..I don't think the big pharms are just going to pass on this opportunity. They are also not a one product company. They sell EKG's and support, and one other filmless xray bone diagnostic tool called the Digital Osteoview 2000. Good Trading! -DavidCG